399 related articles for article (PubMed ID: 29130362)
21. Increased serum concentrations of transforming growth factor-β1 (TGF-β1) in patients with Guillain-Barré syndrome.
Chang KH; Lyu RK; Ro YS; Chen YC; Ro LS; Chang HS; Huang CC; Liao MF; Wu YR; Kuo HC; Chu CC; Chen CM
Clin Chim Acta; 2016 Oct; 461():8-13. PubMed ID: 27450064
[TBL] [Abstract][Full Text] [Related]
22. P-wave dispersion in patients with Guillain-Barré syndrome.
Demirci S; Arslan A; Yürekli VA; Kutluhan S; Koyuncuoğlu HR; Demirci S
Acta Neurol Belg; 2017 Mar; 117(1):289-293. PubMed ID: 27807759
[TBL] [Abstract][Full Text] [Related]
23. Early predictors of functional disability in Guillain-Barré Syndrome.
Tunç A
Acta Neurol Belg; 2019 Dec; 119(4):555-559. PubMed ID: 30963477
[TBL] [Abstract][Full Text] [Related]
24. Alterations of plasma concentrations of lipophilic antioxidants are associated with Guillain-Barre syndrome.
Tang HY; Ho HY; Chiu DT; Huang CY; Cheng ML; Chen CM
Clin Chim Acta; 2017 Jul; 470():75-80. PubMed ID: 28476374
[TBL] [Abstract][Full Text] [Related]
25. HyperCKemia in Guillain-Barré Syndrome.
Choi SJ; Hong YH; Kim JS; Shin JY; Sung JJ
Eur Neurol; 2020; 83(4):415-420. PubMed ID: 32784293
[TBL] [Abstract][Full Text] [Related]
26. Admission sodium level and prognosis in adult Guillain-Barré syndrome.
Sipilä JO; Kauko T; Soilu-Hänninen M
Int J Neurosci; 2017 Apr; 127(4):344-349. PubMed ID: 26971365
[TBL] [Abstract][Full Text] [Related]
27. Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation.
Akboga MK; Canpolat U; Sahinarslan A; Alsancak Y; Nurkoc S; Aras D; Aydogdu S; Abaci A
Atherosclerosis; 2015 May; 240(1):110-4. PubMed ID: 25770689
[TBL] [Abstract][Full Text] [Related]
28. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome.
Altmann P; De Simoni D; Kaider A; Ludwig B; Rath J; Leutmezer F; Zimprich F; Hoeftberger R; Lunn MP; Heslegrave A; Berger T; Zetterberg H; Rommer PS
J Neuroinflammation; 2020 Mar; 17(1):86. PubMed ID: 32183837
[TBL] [Abstract][Full Text] [Related]
29. Free radical toxicity and antioxidants in Guillain-Barre syndrome, a preliminary study.
Kumar KT; Chandrika A; Sumanth KN; Sireesha P; Rao S; Rao A
Clin Chim Acta; 2004 Aug; 346(2):205-9. PubMed ID: 15256322
[TBL] [Abstract][Full Text] [Related]
30. Hyponatremia is a predictor for poor outcome in Guillain-Barré syndrome.
Wang Y; Liu J
Neurol Res; 2015 Apr; 37(4):347-51. PubMed ID: 25366666
[TBL] [Abstract][Full Text] [Related]
31. Toll-like receptor 2 and -4 are involved in the pathogenesis of the Guillain-Barré syndrome.
Du Y; Zhang G; Zhang Z; Wang Q; Ma R; Zhang L; Fan F; Li Y; Wang M; Lv H; Kang X
Mol Med Rep; 2015 Aug; 12(2):3207-13. PubMed ID: 25954926
[TBL] [Abstract][Full Text] [Related]
32. HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome.
Geleijns K; Schreuder GM; Jacobs BC; Sintnicolaas K; van Koningsveld R; Meulstee J; Laman JD; van Doorn PA
Neurology; 2005 Jan; 64(1):44-9. PubMed ID: 15642902
[TBL] [Abstract][Full Text] [Related]
33. Clinical classification of 103 Japanese patients with Guillain-Barré syndrome.
Wakerley BR; Kokubun N; Funakoshi K; Nagashima T; Hirata K; Yuki N
J Neurol Sci; 2016 Oct; 369():43-47. PubMed ID: 27653863
[TBL] [Abstract][Full Text] [Related]
34. Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients.
Ghabaee M; Jabedari B; Al-E-Eshagh N; Ghaffarpour M; Asadi F
Int J Neurosci; 2010 Apr; 120(4):301-4. PubMed ID: 20374079
[TBL] [Abstract][Full Text] [Related]
35. Age may contribute to the increased frequency of axonal Guillain-Barré syndrome.
Hawkes MA; Wilken M; Vázquez G; Farez MF
Muscle Nerve; 2017 Dec; 56(6):1171-1173. PubMed ID: 28467012
[TBL] [Abstract][Full Text] [Related]
36. Demyelinating Guillain-Barré syndrome recurs more frequently than axonal subtypes.
Notturno F; Kokubun N; Sekiguki Y; Nagashima T; De Lauretis A; Yuki N; Kuwabara S; Uncini A
J Neurol Sci; 2016 Jun; 365():132-6. PubMed ID: 27206890
[TBL] [Abstract][Full Text] [Related]
37. Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barré syndrome.
Li C; Zhao P; Sun X; Che Y; Jiang Y
Mediators Inflamm; 2013; 2013():639712. PubMed ID: 24174711
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors and complication rates for double-filtration plasmapheresis in patients with Guillain-Barré syndrome.
Lin JH; Tu KH; Chang CH; Chen YC; Tian YC; Yu CC; Hung CC; Fang JT; Yang CW; Chang MY
Transfus Apher Sci; 2015 Feb; 52(1):78-83. PubMed ID: 25544386
[TBL] [Abstract][Full Text] [Related]
39. Increased plasmacytoid dendritic cells in Guillain-Barré syndrome.
Wang YZ; Feng XG; Wang Q; Xing CY; Shi QG; Kong QX; Cheng PP; Zhang Y; Hao YL; Yuki N
J Neuroimmunol; 2015 Jun; 283():1-6. PubMed ID: 26004148
[TBL] [Abstract][Full Text] [Related]
40. A potential clinical usefulness of measuring serum bilirubin levels in patients with polymyositis.
Peng YF; Zhang L; Pan GG; Wei YS
Eur Rev Med Pharmacol Sci; 2016; 20(4):631-5. PubMed ID: 26957263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
